Tomorrow and next week the first week of the trading year will possibly produce half of the year's return for the broader market, with 5-8 percent returns. Biotech mutual funds could see a 30 percent return by end of 2015.
If you are Long or whatever, get out and suck up your pride, lick your wounds and look for another entry point and then pray, or just walk away and call it a day.
You've got to know when to hold 'em
Know when to fold 'em
Know when to walk away
Know when to run
You never count your money
When you're sittin' at the table
There'll be time enough for countin'
When the dealin's done
Now every gambler knows the secret to survivin'
Is knowin' what to throw away
And knowin' what to keep
'Cause every hand's a winner
And every hand's a loser
And the best that you can hope for
Is to die in your sleep
is $19.02 to $23.75 a share. Let us see what the new year brings. The ZIOPHARM Oncology and biotechnology company stocks have made a nice rebound from the recent so called Flight to Safety plummet that occurred in the Biotechnology sector.
ZIOPHARM Could Increase in Value 4-to-5 Fold, Griffin Securities Says
9:44 AM ET, 12/22/2014
Griffin Securities analyst Keith Markey highlighted ZIOPHARM Oncology (NASDAQ: ZIOP) amid Friday's successful IPO debut for Juno Therapeutics (NASDAQ: JUNO) and the mid-December IPO for Bellicum Pharmaceuticals, noting the two became public companies garnering valuations of $2.7 billion and $511 million, respectively.
Markey notes Ziopharm's valuation led the advance of established public immunotherapy companies, as its price rose 40% off a December 3rd low.
"We attribute the gain to the unveiling of a novel immunotherapy platform that uses genetically modified stem cells to trigger a highly specific immune attack," he said. "The company s valuation stood at $493 million at the market's close last week, while that of its partner, Intrexon Corporation, was $2.8 billion. Elsewhere, Kite Pharma's (NASDAQ: KITE) share price increased 30% since December 1st as discussions of its CAR T-cell program laid the groundwork for a $188 million secondary offering and a valuation of $2.1 billion. The share price of Northwest Biotherapeutics (NASDAQ: NWBO), which does not have genetically modified cells, rose just 13% since December 1st, resulting in a market cap of $357 million. Investors may be awaiting data from a pivotal trial, scheduled to end in September, of its activated dendritic cells against primary brain cancer."
The analyst is looking for Ziopharm s market capitalization to rise markedly as the genetically modified cell therapies developed in collaboration with Intrexon prove themselves in the clinic. "Indeed, the valuations of Juno and Kite point to a potential four- to five-fold increase in its share price on data from early clinical trials," he said.
Buy price target of $12.00
Stockholders are making decent dough as the share price is heating up and some good bread will be made in this market as it continues to rise.
This is the last buying opportunity before the stock begins trading in the $1's. I anticipate that it will take an effort for the stock to break through the $1.00 a share psychological barrier. The stock will eventually close above the dollar mark for 10 consecutive days regaining NASDAQ compliance and then move higher and trade in the teens $1.13 - $1.19 for an elongated period of time, how long elongated will be remains to be seen.
The Company and clinical experts will host an Investor Meeting on Thursday, December 11, 2014 at 7:30 p.m. CT to review the Company’s breast cancer program as well as the Phase 2 results. The meeting will take place in the River Walk Room at the Mokara Hotel & Spa. A live webcast and replay of the presentation will be available on the investor section of the GTx website.